1. Home
  2. BLRX vs SANW Comparison

BLRX vs SANW Comparison

Compare BLRX & SANW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLRX
    SELLHOLDBUYas of 21 hours ago
  • SANW
    SELLHOLDBUYas of 21 hours ago
  • Stock Information
  • Founded
  • BLRX 2003
  • SANW 1980
  • Country
  • BLRX Israel
  • SANW United States
  • Employees
  • BLRX N/A
  • SANW N/A
  • Industry
  • BLRX Biotechnology: Pharmaceutical Preparations
  • SANW Farming/Seeds/Milling
  • Sector
  • BLRX Health Care
  • SANW Consumer Staples
  • Exchange
  • BLRX Nasdaq
  • SANW Nasdaq
  • Market Cap
  • BLRX 12.2M
  • SANW 18.8M
  • IPO Year
  • BLRX 2011
  • SANW 2010
  • Fundamental
  • Price
  • BLRX $3.10
  • SANW $6.94
  • Analyst Decision
  • BLRX Buy
  • SANW Strong Buy
  • Analyst Count
  • BLRX 2
  • SANW 1
  • Target Price
  • BLRX $26.00
  • SANW $35.00
  • AVG Volume (30 Days)
  • BLRX 26.4K
  • SANW 6.1K
  • Earning Date
  • BLRX 05-27-2025
  • SANW 05-13-2025
  • Dividend Yield
  • BLRX N/A
  • SANW N/A
  • EPS Growth
  • BLRX N/A
  • SANW N/A
  • EPS
  • BLRX N/A
  • SANW N/A
  • Revenue
  • BLRX $28,940,000.00
  • SANW $54,809,365.00
  • Revenue This Year
  • BLRX N/A
  • SANW N/A
  • Revenue Next Year
  • BLRX N/A
  • SANW $14.25
  • P/E Ratio
  • BLRX N/A
  • SANW N/A
  • Revenue Growth
  • BLRX 502.92
  • SANW N/A
  • 52 Week Low
  • BLRX $2.85
  • SANW $2.10
  • 52 Week High
  • BLRX $35.60
  • SANW $11.60
  • Technical
  • Relative Strength Index (RSI)
  • BLRX 41.70
  • SANW 40.59
  • Support Level
  • BLRX $3.01
  • SANW $6.73
  • Resistance Level
  • BLRX $3.61
  • SANW $8.22
  • Average True Range (ATR)
  • BLRX 0.22
  • SANW 0.64
  • MACD
  • BLRX 0.02
  • SANW -0.05
  • Stochastic Oscillator
  • BLRX 32.89
  • SANW 19.51

Stock Price Comparison Chart: BLRX vs SANW

BLRX
SANW
JulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025April05101520253035BLRX VS SANW

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

About SANW S&W Seed Company (NV)

S&W Seed Co is a multi-crop, middle-market agricultural company. It is engaged in the breeding, production, and sale of alfalfa seed and sorghum seed. It also has a growing commercial market presence in sunflower and maintains an active stevia development program. The company's seed platform develops and supplies germplasm designed to produce higher yields for farmers globally. Its geographical segments include the United States, Australia, Saudi Arabia, Mexico, South Africa, and other countries. Maximum of revenue is earned from USA following Australia second and Mexico third.

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use